Aquestive Therapeutics (NASDAQ:AQST) resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration for Anaphylm (dibutepinephrine) sublingual film, a treatment candidate for Type I allergic reactions including anaphylaxis.
NGL Energy Partners (NYSE:NGL) announced that its Board of Directors declared quarterly distributions for its Class B, Class C and Class D preferred units for the quarter ending September 30, 2026.
Surf Air Mobility (NYSE:SRFM) announced a definitive agreement with Sprintbach Aviation for OperatorOS, its SurfOS flight operations software platform for Part 135 operators powered by Palantir Technologies (NASDAQ:PLTR).
Aethlon Medical (NASDAQ:AEMD) and North Immunology entered a definitive all-stock merger agreement that will combine the companies around NOR-101, a half-life extended IL-13 x IL-18 bispecific antibody being developed for atopic dermatitis and other immune-mediated diseases.
Sanofi (NASDAQ:SNY) and Cheplapharm announced plans to create a strategic partnership under which Cheplapharm would acquire a portfolio of 20 mature medicines and three manufacturing sites from Sanofi, with Sanofi receiving a 26.4% equity stake in Cheplapharm.
Global Net Lease (NYSE:GNL) declared quarterly cash dividends on all outstanding preferred stock series, with payments scheduled for October 15, 2026.
Tower Semiconductor (NASDAQ:TSEM) and NewPhotonics announced the start of high-volume shipments of laser-integrated, serviceable optical engine photonic integrated circuits (PICs) designed for AI data-center interconnects.
111 (NASDAQ:YI) received an unsolicited, preliminary and non-binding proposal from a buyer group to acquire all outstanding Class A ordinary shares not already owned by the group and take the company private.
Brent crude futures declined 1.8% to $103.95 a barrel and U.S. West Texas Intermediate (WTI) futures fell 1.7% to $100.66 a barrel after reports that Saudi Arabia was offering additional crude cargoes through Oman, easing some supply concerns.
Innate Pharma (NASDAQ:IPHA) reported revenue and other income of €5.7 million for the first half of 2026, while posting a net loss of €19.6 million as the biotechnology company adjusted its research and development activities.
GARANTA JÁ SEU GRAFA EDGE
Vamos ativar um teste de 30 dias do Edge como presente de boas-vindas
